In recent years, market access has grown in power and become increasingly complex in structure. With health systems and managed care organizations continuing pressure to control the cost of patient care as well as the greater emphasis on value-based outcomes, healthcare manufacturers must navigate a challenging landscape of obstacles in order to ensure that their products are made available to patients and reimbursed in as many markets as possible.
Dynamic Practice Simulation® is the most lifelike Marketing Research prescribing simulation available in healthcare today. DPS® creates “real” patient profiles from as many as 20 different variables, which empowers you to observe treatment choices for a diverse patient population. Physicians “prescribe” on a realistic ERx tool, which enables you to test the impact of real-time adjudication and changes in formulary status on prescribing behavior.
Whether you are evaluating an acquisition, predicting the success of a new indication, or estimating the potential of a new market, RG+A’s innovative healthcare industry forecasting methods are designed to provide you with reliable insights – even in the face of uncertainty. With flexible tools such as RG+A’s pioneering Dynamic Practice Simulation®, you can have confidence in the outcome, no matter what the circumstances.
QTM is a modeling tool that provides support for pivotal decisions when time, budget, or available sample are in short supply. In QTM, we build Monte Carlo forecast models by integrating your previous primary marketing research with secondary data and RG+A-run qualitative interviews. The resulting model’s greatest value lies in the ability to predict probably of achieving a market share, revenue, or financial goal. It also identifies the market factors that will be most pivotal in whether you achieve goal or not, and a number to use in a spot forecast.
DPS®/conjoint combines the behavioral realism and analytical power of DPS® with conjoint’s ability to measure the relative impact of different variables and performance levels on market behavior. This tool is particularly useful in designing late-stage clinical trials and forecasting share and revenue for products or indications that have yet to come to market.
Qualitative Conjoint enables our clients to conduct trade-off exercises even when the available sample is not sufficient for quantitative research. Statistical techniques such as bootstrapping increase the precision of the conjoint estimates, and such a study even enables our clients to identify segments within the sample.
Line of Therapy is a specific application of Dynamic Practice Simulation® designed for progressive diseases. In diseases ranging from oncology to diabetes, each line of therapy affects later line choices. DPS® Line of Therapy simulates how a physician might treat a patient from the beginning of a disease throughout its progression. It is particularly valuable when you are trying to move a product earlier in treatment, assessing maintenance vs. acute phase products, or seeking to determine which combination of patient characteristics and prior therapies shape later-line treatment decisions.
Payer Scope utilizes HPC to explore an important payer issue quickly and in tremendous depth. This small sample method begins with a set of telephone depth interviews that provide an initial sense of individuals’ knowledge, beliefs, and actions. From there, participants engage in a multi-stage web exercise designed to determine issues on which respondents agree and others on which opinions vary. It ends with an estimating exercise that provides inputs for forecasts and probability models.
Contract Simulation provides a realistic and intricate look at how clients will negotiate a contract for your product. The core of this method is a multi-day simulation of the actual negotiation process, with RG+A playing the role of client-side negotiator while simultaneously moderating the process. A conjoint at the back end of negotiations provides a model you can use in estimating the impact of contracting decisions. Clients have used this method with payers, hospitals, and practice managers considering buy-and-bill products.
Co-creation is an increasingly common way to enroll multiple stakeholders in building solutions to complex issues.
At RG+A, we have added the wrinkle of bringing anonymized Managed Markets stakeholders into collaboration with several different corporate stakeholders (commercial, regulatory, HEOR, medical) with executives in Managed Markets organizations. Clients use this method to address complex methods, or to help groups that do not usually interact with payers to see the world through this customer class’s point of view.
Sometimes it is critical to know how payers will feel about an event or topic – fast. Our HPI methodology leverages the Health Payer Council to collect qualitative reactions to a stimulus (profile, article, question, etc.) from 20+ Pharmacy and Medical Directors in two weeks or less.
Consumer Cascade is a series of quantitative questions that capture every pivotal decision a patient makes during the course of therapy from the initial decision to seek treatment to the final purchase of a more expensive branded medication that the prescriber has recommended over the generic. Given the increasing importance of the consumer in the prescribing and fulfillment processes, Consumer Cascade is a pivotal element in building future-focused market models.
Forecasting the impact of market events – whether estimating new product share, predicting payer coverage, or quantifying a competitive threat – is critical to your brand’s success. With reduced budgets, tighter timelines, and smaller sample sizes, how can you produce the most accurate forecasts with as much precision as possible? RG+A’s Wisdom of Crowds approach speaks directly to this need.